Back to Articles

The July 2026 PCAC Meeting: What's at Stake for BPC-157, TB-500, Semax, and More

April 19, 20267 min readTruPeptide Editorial

The Most Important Peptide Regulatory Event of 2026

On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) will convene to evaluate seven peptide compounds and make recommendations on whether they should be formally added to the 503A bulk drug substances list — the list that authorizes licensed compounding pharmacies to prepare them for patients.

This meeting is the direct result of the April 15, 2026 FDA announcement that removed 12 peptides from the Category 2 "significant safety risks" list. That removal was a necessary first step, but it was not authorization. The PCAC meeting is where the actual determination happens.

For anyone who uses, prescribes, or follows BPC-157, TB-500, Semax, Epitalon, MOTs-c, KPV, or Emideltide — this is the meeting that matters.

What the PCAC Is and How It Works

The Pharmacy Compounding Advisory Committee is an FDA advisory body that evaluates bulk drug substances nominated for use in compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act.

The process works like this:

  1. Nominations are submitted by industry stakeholders, researchers, or patient advocates
  2. FDA staff prepare a briefing document summarizing the evidence for each compound
  3. PCAC members review the briefing, hear presentations from nominators and the public, and deliberate
  4. The committee votes on whether to recommend adding each compound to the 503A bulks list
  5. FDA decides whether to accept, modify, or reject the recommendation — the committee is advisory, not binding

The meetings are public and streamed live. Written public comments submitted by July 9, 2026 are provided directly to the committee. Oral presentation requests must be submitted by June 30, 2026.

Public comment docket: FDA-2025-N-6895

The Seven Compounds Under Review

July 23, 2026

BPC-157 (Body Protection Compound-157) The most widely discussed compound on the list. A synthetic 15-amino acid peptide derived from gastric juice, studied extensively in animal models for tissue repair, gut healing, and anti-inflammatory effects. The FDA's listed indication for PCAC review is ulcerative colitis. Community use is primarily for injury recovery and gut health. The evidence base is almost entirely preclinical — human trials are limited.

TB-500 (Thymosin Beta-4 Fragment) A synthetic fragment of thymosin beta-4, studied for wound healing and tissue repair. Strong animal data, limited human clinical trials. Widely used in the biohacking and athletic recovery communities. FDA's listed indication: wound healing.

MOTs-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) A mitochondria-derived peptide with emerging research on metabolic health, insulin sensitivity, and exercise capacity. One of the more scientifically novel compounds on the list. FDA's listed indications: obesity and osteoporosis.

KPV (Lys-Pro-Val) A tripeptide derived from alpha-MSH with potent anti-inflammatory properties. Studied for inflammatory bowel conditions and wound healing. FDA's listed indications: wound healing and inflammatory conditions.

July 24, 2026

Emideltide (DSIP — Delta Sleep-Inducing Peptide) A nonapeptide originally studied for sleep induction, now being evaluated for opioid withdrawal and chronic insomnia. FDA's listed indications: opioid withdrawal, chronic insomnia, narcolepsy.

Epitalon A synthetic tetrapeptide developed in Russia, studied for telomere lengthening, melatonin regulation, and anti-aging properties. Most research originates from Russian institutions. FDA's listed indication: insomnia.

Semax A synthetic heptapeptide analog of ACTH(4-10) with decades of clinical use in Russia for cerebral ischemia and cognitive impairment. FDA's listed indications: cerebral ischemia and trigeminal neuralgia.

What Outcomes Are Possible

For each compound, the PCAC can recommend one of three outcomes:

Add to the 503A bulks list — The compound is formally authorized for compounding by licensed 503A pharmacies with a physician prescription. This is the outcome patients and clinicians are hoping for.

Do not add — The compound is not placed on the bulks list. It would likely be placed in the "Other Bulk Drug Substances That May Present Significant Safety Risks" category, effectively returning it to restricted status.

Needs more data — The committee requests additional evidence before making a final recommendation. This delays resolution but doesn't foreclose a positive outcome.

The PCAC recommendation is advisory. The FDA retains authority to accept, modify, or reject it. Given the current administration's stated support for broader peptide access, outcomes may differ from prior PCAC precedent — which, under the Biden administration, voted against inclusion for similar withdrawn nominations.

The Political Context

This meeting doesn't happen in a vacuum. HHS Secretary Robert F. Kennedy Jr. has publicly championed peptide access, called the 2023 Category 2 designations "illegal," and framed the regulatory reversal as a public health measure to eliminate a dangerous gray market.

The administration has the authority to appoint PCAC members, and several positions are currently vacant. The composition of the reconstituted committee — including any new appointments made before July — will be a significant factor in how the votes go.

Critics, including Public Citizen's Health Research Group, have raised concerns that the process is being driven by political pressure rather than scientific evaluation. "There is no credible reason to believe that peptides that were deemed unproven or unsafe in 2023 are miraculously safe and effective in 2026," the organization stated in April.

Both perspectives are worth understanding. The science on most of these compounds is genuinely limited in humans. The policy question — whether limited evidence justifies prohibition or regulated access — is legitimately contested.

What This Means for Patients Right Now

If you're currently using these peptides through a licensed clinic: The regulatory gray zone created by the April 22 Category 2 removal continues until PCAC acts. Clinics and compounding pharmacies are navigating this carefully. The July meeting is the next major milestone.

If you've been sourcing from gray-market vendors: The regulatory trajectory strongly points toward a legitimate compounding pathway opening. The administration's explicit goal is to replace unregulated imports with "ethical suppliers" — licensed compounding pharmacies with pharmaceutical-grade ingredients and COA documentation.

If you're considering starting peptide therapy: The safest path remains through a licensed telehealth clinic that works with a regulated compounding pharmacy. See our Clinic Directory for verified options.

Key Dates to Track

| Date | Event | |------|-------| | June 30, 2026 | Deadline to request oral presentation at July PCAC meeting | | July 9, 2026 | Public comment deadline (docket FDA-2025-N-6895) | | July 23, 2026 | PCAC Day 1: BPC-157, KPV, MOTs-c, TB-500 | | July 24, 2026 | PCAC Day 2: Emideltide, Epitalon, Semax | | TBD (by Feb 2027) | PCAC Group 2: GHK-Cu, Melanotan II, Cathelicidin LL-37, Dihexa, PEG-MGF |

How to Participate

The PCAC process is public and participatory. If you have a perspective on any of these compounds — as a patient, clinician, researcher, or advocate — you can submit a written comment directly to the committee.

Submit a comment:

  1. Go to regulations.gov
  2. Search for docket FDA-2025-N-6895
  3. Click "Comment" and submit your written statement
  4. Comments submitted by July 9 will be provided to the committee

Comments don't need to be formal or technical. Patient experience, clinical observations, and safety concerns are all relevant. The committee is required to consider public input.

What Comes After July

The July meeting covers seven compounds. A second PCAC meeting, scheduled before the end of February 2027, will cover the remaining five: Cathelicidin LL-37, Dihexa, GHK-Cu (all routes), PEG-MGF, and Melanotan II.

After each meeting, the FDA will review the committee's recommendations and issue final determinations. The timeline for those determinations is not fixed — it could be weeks or months after each meeting.

TruPeptide will update the FDA Tracker and publish same-day coverage of the July 23–24 meeting outcomes. Subscribe to the newsletter to get that coverage delivered directly.

Sources: FDA Federal Register Notice · Orrick Law Firm Analysis · RAPS

This article is for educational and informational purposes only and does not constitute medical or legal advice.